{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rosen LE"],"funding":["National Institute of Allergy and Infectious Diseases","PEW Charitable Trusts","Searle Scholars Program","Howard Hughes Medical Institute","NIAID NIH HHS","Burroughs Wellcome Fund","Vir Biotechnology Inc","NCI NIH HHS","Damon Runyon Cancer Research Foundation","NIGMS NIH HHS"],"pagination":["7196-7213.e26"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11645210"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["187(25)"],"pubmed_abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for mAbs that are resilient to epitope diversification. Broadly neutralizing coronavirus mAbs that are sufficiently potent for clinical development and retain activity despite viral evolution remain elusive. We identified a human mAb, designated VIR-7229, which targets the viral receptor-binding motif (RBM) with unprecedented cross-reactivity to all sarbecovirus clades, including non-ACE2-utilizing bat sarbecoviruses, while potently neutralizing SARS-CoV-2 variants since 2019, including the recent EG.5, BA.2.86, and JN.1. VIR-7229 tolerates extraordinary epitope variability, partly attributed to its high binding affinit"],"journal":["Cell"],"pubmed_title":["A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification."],"pmcid":["PMC11645210"],"funding_grant_id":["P30 CA042014","DP1 AI158186","P30 CA008748","P30 GM133894","F31 AI174573","P30 GM124169","P01 AI167966","75N93022C00036"],"pubmed_authors":["Bohan D","Rajesh A","Zhang I","Guarino B","Tsu B","di Iulio J","Starr TN","Schnell G","Czudnochowski N","Park YJ","Corti D","Rietz T","Sprouse KR","Addetia A","Taylor AL","Benigni F","Subramanian S","Errico JM","DaCosta Y","Tortorici MA","Schmid MA","Pizzuto MS","Noack J","Rosen LE","Acosta R","Whelan SPJ","De Marco A","Hauser K","Dang HV","Telenti A","Chartron JW","Pinto D","Lanzavecchia A","Bourhy H","Dellota E","Cameroni E","Lee J","Kergoat L","Foreman WB","de Melo GD","Liu Z","Cusumano G","Purcell LA","Veesler D","Lempp FA","Snell G","Zatta F","Saliba C","Brown J","Miller JL","Giurdanella M","Zepeda SK","Tao Q"],"additional_accession":[]},"is_claimable":false,"name":"A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification.","description":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for mAbs that are resilient to epitope diversification. Broadly neutralizing coronavirus mAbs that are sufficiently potent for clinical development and retain activity despite viral evolution remain elusive. We identified a human mAb, designated VIR-7229, which targets the viral receptor-binding motif (RBM) with unprecedented cross-reactivity to all sarbecovirus clades, including non-ACE2-utilizing bat sarbecoviruses, while potently neutralizing SARS-CoV-2 variants since 2019, including the recent EG.5, BA.2.86, and JN.1. VIR-7229 tolerates extraordinary epitope variability, partly attributed to its high binding affinit","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-03T03:08:27.281Z","creation":"2025-04-04T01:54:34.999Z"},"accession":"S-EPMC11645210","cross_references":{"pubmed":["39383863"],"doi":["10.1016/j.cell.2024.09.026"]}}